Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices
Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices
复制标题
DOI：
10.1016/j.berh.2005.03.010
复制
发表时间：
2005-10-01
影响因子：
5.2
通讯作者：
Gordon, C
中科院分区：
文献类型：
--
作者：
Griffiths, B;Mosca, M;Gordon, C
系统性红斑狼疮（SLE）疾病活动性的评估是临床医生在日常护理中面临的任务，但它也是临床研究和随机对照试验所需的。区分疾病活动与感染、慢性损伤和共病至关重要。在过去的20年里，已经开发了许多指标来客观地测量狼疮疾病的活动性，其中一些已经得到验证。最广泛使用的指数是不列颠群岛狼疮评估组（BILAG）指数、欧洲共识狼疮活动测量（ECLAM）、系统性狼疮活动测量（SLAM）、系统性红斑狼疮疾病活动指数（SLEDAI）和狼疮活动指数（LAI）。所有指标均经过验证，具有良好的信度、效度和变化反应性。除了评估疾病活动性外，建议临床研究使用经验证的SLICC/ACR损伤指数和健康相关生活质量评价损伤。
The assessment of disease activity in systemic lupus erythematosus (SLE) is a task faced by clinicians in every day care, but it is also required for clinical research and in randomised controlled trials. It is crucial to distinguish disease activity from infection, chronic damage and co-morbid disease. Over the past 20 years, many indices have been developed to objectively measure lupus disease activity and several of these have been validated. The most widely used indices are the British Isles Lupus Assessment Group (BILAG) index, the European Consensus Lupus Activity Measurement (ECLAM), the Systemic Lupus Activity Measure (SLAM), the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Lupus Activity Index (LAI). All these indices have been validated and have excellent reliability, validity and responsiveness to change. In addition to the assessment of disease activity, the evaluation of damage using the validated SLICC/ACR damage index and health-related quality of life is advised for clinical research.